

Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

B-Raf (55C6) Rabbit mAb

RRID:AB_2259354

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9433, RRID:AB_2259354

Antibody Information

URL: http://antibodyregistry.org/AB_2259354

Proper Citation: Cell Signaling Technology Cat# 9433, RRID:AB_2259354

Target Antigen: BRAF

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W. Consolidation on 11/2018: AB_10692521, AB_2259354.

Antibody Name: B-Raf (55C6) Rabbit mAb

Description: This monoclonal targets BRAF

Target Organism: rat, human

Antibody ID: AB_2259354

Vendor: Cell Signaling Technology

Catalog Number: 9433

Record Creation Time: 20250819T220225+0000

Record Last Update: 20250820T005451+0000

Ratings and Alerts

No rating or validation information has been found for B-Raf (55C6) Rabbit mAb.

No alerts have been found for B-Raf (55C6) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Nokin MJ, et al. (2024) In?vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma. Cell reports. Medicine, 5(8), 101663.

Ta L, et al. (2023) Wild-type C-Raf gene dosage and dimerization drive prostate cancer metastasis. iScience, 26(12), 108480.

Jian C, et al. (2020) Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. Cell metabolism, 31(5), 892.

Klotz-Noack K, et al. (2020) SFPQ Depletion Is Synthetically Lethal with BRAFV600E in Colorectal Cancer Cells. Cell reports, 32(12), 108184.

Wang X, et al. (2019) AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness. Developmental cell, 48(3), 345.

Chan LH, et al. (2018) PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation. Cell reports, 25(3), 690.

Pan R, et al. (2017) Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer cell, 32(6), 748.